Yuhan Corporation Signs Joint Promotion Agreement with J&J for "Leclaza Combination Therapy" in Korea

Yuhan Corporation announced that it will jointly conduct domestic promotional activities for the combination therapy of "Leclaza® (lazertinib) - Rybrevant® (amivantamab)" for non-small cell lung cancer with Janssen Korea, the pharmaceutical division of Johnson & Johnson's Korean subsidiary.

The two companies held a signing ceremony on the 31st of last month and agreed to launch joint promotional activities for the Leclaza®-Rybrevant® combination therapy.

Jo Ukje, CEO of Yuhan Corporation (right), and Christian Rodses, CEO of Janssen Korea, are taking a commemorative photo after the signing ceremony on the 31st of last month. Yuhan Corporation

Until now, domestic promotional activities for the Leclaza®-Rybrevant® combination therapy have been led by Johnson & Johnson, which holds the global rights. With this new agreement, Yuhan Corporation will participate in the joint promotion. Previously, Yuhan Corporation was responsible for promoting Leclaza® monotherapy, but with this agreement, its role will expand to include joint promotion of the combination therapy.

With this agreement, the two companies plan to establish a close collaborative system to expand access to the Leclaza®-Rybrevant® combination therapy. Distribution of each therapy will remain unchanged: Johnson & Johnson will continue to distribute Rybrevant®, while Yuhan Corporation will handle Leclaza®.

Rybrevant® is the first bispecific antibody to simultaneously inhibit both EGFR and MET, while Leclaza® is a third-generation EGFR tyrosine kinase inhibitor (TKI). The joint marketing of this combination therapy is based on the significant clinical efficacy and safety profile demonstrated in the global Phase III clinical trial (MARIPOSA) for the Rybrevant®-Leclaza® combination. The initiative was planned as a mutual agreement between the two companies to actively inform domestic healthcare professionals of the therapeutic value of the combination therapy and to improve treatment accessibility.

Joo Wookje, CEO of Yuhan Corporation, stated, "Leclaza® has set a new milestone as a domestically developed lung cancer therapy for EGFR-mutant non-small cell lung cancer. As the Leclaza®-Rybrevant® combination therapy has proven its therapeutic value through clinical research, we will actively collaborate with Janssen Korea to ensure it is firmly established as a first-line treatment for EGFR-mutant non-small cell lung cancer."

The Leclaza®-Rybrevant® combination therapy received approval from the Ministry of Food and Drug Safety in January of this year as a first-line treatment for non-small cell lung cancer with EGFR exon 19 deletion or exon 21 (L858R) substitution mutations.

This content was produced with the assistance of AI translation services.